Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?

European Urology

Volumn 44, Issue 1, 2003, Pages 57-64

  Kuczyk, M ^a   Turkeri, Levent ^b   Hammerer, Peter ^c   Ravery, Vincent ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c University of Medical School Hamburg Eppendorf   (Germany)

^d BICHAT HOSPITAL   (France)

Author keywords

Bladder cancer; Bladder sparing treatment; Radical cystectomy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; RADIOSENSITIZING AGENT; VINBLASTINE;

BLADDER CANCER; BLADDER SPARING THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DRUG RESPONSE; HEALTH CARE COST; HUMAN; MORBIDITY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSENSITIZATION; REVIEW; SIDE EFFECT; TRANSURETHRAL RESECTION;

EID: 0037974495     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00150-7     Document Type: Review

References (73)

1. Abratt RP, Wilson JA, Pontin AR, et al. Salvage cystectomy after radical irradiation for bladder cancer: prognostic factors and complications. Br J Urol 1993;72:756.
2. Barnes RW, Dick AL, Hadley HL, et al. Survival following transurethral resection of bladder carcinoma. Cancer Res 1997;37:2895.
3. Bloom HJ, Hendry WF, Wallace DM, et al. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 1982;54:136.
4. Brendler CB, Steinberg GD, Marshall FF, et al. Local recurrence and survival following nerve-sparing radical cystoprostatectomy. J Urol 1990;144:1137.
5. Cancrini A, De Carli P, Pompeo V, et al. Lower urinary tract reconstruction following cystectomy: experience and results in 96 patients using the orthotopic ileal bladder substitution of Studer et al. Eur Urol 1996;29:204.
6. Christiano AP, Hollowell CMP, Steinberg GD. Impact of Hautmann neobladder chimney modification on ureteral stenosis. J Urol 1999;161(Suppl):252A.
7. Cox JD, Guse C, Asbell S, et al. Tolerance of pelvic noirmal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1988;15:1331.
8. DeNeve W, Lybeert ML, Goor C. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Rad Oncol 1995;36:183.
9. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299.
10. Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A. An organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Rad Oncol Biol Phys 1994;30:261.
11. Einstein AB, Wolf M, Halliday KR, et al. Combination of transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study. Urology 1996;47:652.
12. Farah R, Chodak GW, Vogelzang NJ, Awan AM, Quiet CA, Moormeier J, et al. Curative radiotherapy folowing chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Rad Oncol Biol Phys 1991;20:413.
13. Fellin G, Graffer U, Bolner A, et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 1997;80:44.
14. Frazier HA, Robertson JE, Dodge RK, et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993;71:3993.
15. Geven KM, Spera JA, Solin LJ, Morgan T, Hanks GE. Local control after cystectomy alone in bladder carcinoma. Cancer 1992;69:2767.
16. Given RW, Parsons JT, McCarley D, Wajsman Z. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a fiveyear follow-up. Urology 1995;46:499.
17. Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MAS, Thomas GM, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448.
18. Gospodarowicz MK, Quilty PM, Scalliet P, Tsuji H, Fossa SD, Horenblas S, et al. The place of radiation therapy as definite treatment of bladder cancer. Int J Urol 1995;(Suppl 2):41.
19. Hall RR. Transurethral resection for transitional cell carcinoma. Prob Urol 1992;6:460.
20. Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, Smith PM. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984;56:668.
21. Hall RR, Roberts JT. Neoadjuvant chemotherapy, a method to conserve the bladder? Eur J Cancer 1991;27(Suppl 2):29.
22. Hart S, Skinner EC, Meyerowitz BE, et al. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, or cutaneons or urethral kock pouch. J Urol 1999;162:77.
23. Hautmann RE. Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur Urol 1998;33(Suppl):23.
24. Hautmann RE, de Petriconi R, Gottfried H-W, et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999;161:422.
25. Henry K, Miller J, Mort M, Loening S, Fallon B. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 1988;140:964.
26. Herr HW. Conservative mnanagement of muscle infiltrating bladder tumors: prospective experience. J Urol 1987;138:1162.
27. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74.
28. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593.
29. Horoit JC, LeFur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 1992;25:231.
30. Horwich A, Pendlebury S, Dearnaley DP. Organ conservation in bladder cancer. Eur J Cancer 1995;31(suppl):208.
31. Housset M, Dufour E, Maulard-Durtux C. Concomitant 5-fluouracil cisplatin and bifractionated split course radiation therapy for invasive bladder cancer. Proc Am Soc Clin Oncol 1997;16:1139A.
32. Housset M, Maulard C, Chretien YC, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitionalcell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150.
33. Jenkins BJ, Caulfield MJ, Fowler CG, Badenoch DF, Tiptaft RC, Paris AM, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988;62:343.
34. Jung P, Jakse G. Bladder preservation in invasive locally confined bladder cancer. Onkologie 1996;19:296.
35. Kachnic LA, Kaufman DS, Griffin PP, Heney NM, Althausen AF, Zietman AL, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022.
36. Keating JP, Zincke H, Morgan WR, Hahn RG. Extended experience with neoadjuvant (M-VAC) chemotherapy for invasive transitional cell carcinoma (TCC) of the urinary bladder. J Urol 1989;141:244A.
37. Klan R, Loy V, Huland H. Residual tumor discovered in routine second TUR in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316.
38. Kolettis PN, Klein EA, Novick AC, et al. The Le Bag orthotopic urinary diversion. J Urol 1996;156:926.
39. Lynch WJ, Jenkins BJ, Fowler CG, et al. The quality of life after radical radiotherapy for bladder cancer. Br J Urol 1992;70:519.
40. Maffezzini M, Torelli T, Villa E, Corrada P, Bolognesi A, Leidi GL, et al. Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: local tumor response and early followup results. J Urol 1991;145:741.
41. Malmström P-U, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. J Urol 1996;155:1903.
42. Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definite radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995;31:247.
43. Martinez-Pineiro JA, Gonzalez Martin M, Arocena NF, Flores N, Roncero CR, Portillo JA, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995;153:964.
44. Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1977;39(suppl):973.
45. Montie JE, Straffon RA, Stewart BH. Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol 1984;131:477.
46. Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol 1994;33:397.
47. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical eystectomy for invasive bladder cancer: a clinicopathological study with an amphasis on the inadequacy of the tumor. J Urol 1991;145:45.
48. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994;30:267.
49. Pressler LB, Petrylak DP, Olsson CA. Invasive transitional cell carcinoma of the bladder: prognosis and management. In: Oesterling JE, Richie JP. editors. Urologic Oncology. Saunders WB. Philadelphia, 1997; p. 275-91.
50. Prout GR, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, et al. Preliminary results in invasive bladder cancer with transurethral resection. J Urol 1990;144:1128.
51. Quilty PM, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 1986;12:853.
52. Roberts JT, Fossa SD, Richards B, Kaye SB, White EF, Robinson MC, et al. Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder. Br J Urol 1991;68:162.
53. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998;40:121.
54. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988;139:470.
55. Schoenberg MP, Walsh PC, Breazeale Dr, et al. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer. J Urol 1996;155:490.
56. Schultz PK, Herr HW, Zhang ZF, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994;12:1394.
57. Sell A, Jacobsen A, Nerstrom B. Treatment of advanced bladder cancer category T2, T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol 1991;138(suppl):193.
58. Shearer RJ, Chilvers CF, Bloom HJG, Bliss JM, Horwich A, Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder. Br J Urol 1988;62:558.
59. Shipley WU, Kaufman DS, Hen NM, et al. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol 1998;33(suppl):32.
60. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576.
61. Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Invasive bladder cancer: treatment strategies using transurethral surgery. Int J Rad Onc Biol Phys 1997;39:937.
62. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984;131:1069.
63. Skinner DG, Stein JP, Lieskovsky G, et al. 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998;33(Suppl):25.
64. Smaaland R, Akslen LA, Tonder B, Mehus A, Lote K, Albrektsen G. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol 1991;67:61.
65. Srougi M, Simon SD. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy in bladder preservation in locally invasive bladder cancer: a 5-year followup. J Urol 1994;151:593.
66. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645.
67. Stenzl A, Colleselli K, Poisel S, et al. Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women. J Urol 1995;154:2044.
68. Sternberg CN, Raghaven D, Ohi Y, Bajorin D, Herr H, Kato T, et al. Neoadjuvant and adjuvant chemotherapy in advanced disease - what are the effects on survival and prognosis? Int J Urol 1995;2(Suppl):76.
69. Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119.
70. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder cancer: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25:783.
71. Waehre H, Ous S, Klevmark B, et al. A bladder cancer multiinstitutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993;72:3044.
72. Whitmore WF, Batata MA, Ghoneim MA, Grabstald H, Unal A. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 1977;118:184.
73. Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent ciplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:1673.